Shares of ABVC BioPharma, Inc. (NASDAQ:ABVC - Get Free Report) traded up 1.7% during trading on Tuesday . The company traded as high as $3.72 and last traded at $3.57. 398,263 shares were traded during mid-day trading, an increase of 11% from the average session volume of 357,924 shares. The stock had previously closed at $3.51.
ABVC BioPharma Trading Down 6.4%
The stock has a market capitalization of $56.89 million, a P/E ratio of -25.77 and a beta of 0.37. The stock's fifty day moving average price is $2.18 and its two-hundred day moving average price is $1.23.
ABVC BioPharma (NASDAQ:ABVC - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.06) EPS for the quarter. ABVC BioPharma had a negative net margin of 963.46% and a negative return on equity of 29.62%.
Institutional Trading of ABVC BioPharma
An institutional investor recently raised its position in ABVC BioPharma stock. XTX Topco Ltd boosted its position in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC - Free Report) by 75.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 60,439 shares of the company's stock after acquiring an additional 26,034 shares during the period. XTX Topco Ltd owned 0.36% of ABVC BioPharma worth $64,000 at the end of the most recent quarter. 11.38% of the stock is currently owned by institutional investors and hedge funds.
ABVC BioPharma Company Profile
(
Get Free Report)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
Further Reading
Before you consider ABVC BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABVC BioPharma wasn't on the list.
While ABVC BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
